Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Hikma Pharmaceuticals PLC

HIK.L ✓ COMPLIANT ☆ Track — members

LSE · Healthcare · Pharmaceuticals ·

UK Mid Cap Analyst: BUY

Last Close

$21.61

▼ -0.25%

Market Cap $4.51B · Vol 504.10K

Key Metrics

P/E Ratio

12.31

FWD: 9.05

Market Cap

$4.51B

Mid Cap

Div Yield

3.96%

Semi-annual dividend

EPS Growth

-0.36%

YoY

RSI (14)

22.81

Momentum

Beta

0.92

vs Market

52W High

$25.25

13.68% below

52W Low

$16.07

35.95% above

Volume

504.10K

Avg 965.20K

P/B

1.79

Price-to-book

ROE

20.52%

Return on equity

Free Float

66.02%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Hikma Pharmaceuticals PLC (HIK.L) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HIK.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.18%

-4.83%

+9.09%

+32.01%

YTD

+2.97%

-6.06%

-16.90%

-36.79%

Financials & Valuation

TTM · Annual

Total Revenue	$3.35B
Net Income	$407.00M
Revenue Growth (YoY)	+4.28%
Gross Margin	40.52%
Operating Margin	19.17%
Net Profit Margin	12.15%
ROE	20.52%
ROA · ROIC	9.61% · 12.24%

P/E Ratio	12.31
Forward P/E (FY1)	9.05
PEG Ratio	0.93
P/S	1.39
P/B	1.79
P/FCF	108.15
EPS Growth	-0.36%
Outstanding Shares	208.75M

Technical Indicators

50-Day SMA	$21.67
200-Day SMA	$20.17
RSI (14)	22.81
Beta	0.92
52-Week High	$25.25
52-Week Low	$16.07

Volume Today	504.10K
Avg Daily Volume (30D)	965.20K
Relative Volume	0.52x
Volatility (10D)	6.23
Volatility (30D)	26.21
Free Float	66.02%

Analyst Consensus

BUY

Current Price $21.61

Mean Target $25.84

52W Low$16.07 52W High$25.25

Current

Target

$16.07 $25.25

Current Analyst target

+19.59% upside potential · 12 analysts

Identifiers

ExchangeLSE

FIGIBBG001SNK879

ISINGB00B0LCW083

CountryUnited Kingdom

Sub-IndustryPharmaceuticals (NEC)

Earnings DateFeb 24, 2027

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.21% JNJ Johnson & Johnson -2.22% ABBV Abbvie Inc -2.99% NVS Novartis AG -13.93% NOVN.S Novartis AG -10.89%

Company Profile

Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and non-licensed pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. It supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). It supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. It supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.